DXCM
Dexcom
October 15, 2026 · pre-market
- Rarity
- 1.16
- Peak move
- +5.07%
- Float cap
- $31.5B
Dexcom designs and sells continuous glucose monitoring (CGM) systems — a wearable sensor, transmitter and receiver/app — that track glucose levels in real time for people with type 1 and type 2 diabetes, as well as for prediabetic and non-insulin users through its over-the-counter Stelo product. It sells to patients, caregivers, clinicians, and health plans, largely in the United States with growing international sales.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
3 events · 0 from SEC or newswire · 0 timed with the moveclinical_readoutDexcom announced that results from the CONNECT randomized controlled trial of its Dexcom G7 CGM in adults with Type 2 diabetes not on insulin were published in The New England Journal of Medicine, showing a 1.6% average A1C reduction from an 8.8% baseline (0.9% greater than routine care) and about five more hours per day in the 70-180 mg/dL target range.
analyst_ratingMizuho analyst Anthony Petrone raised his price target on DexCom (DXCM) to $100 from $95 while keeping an Outperform rating, as part of a Q3 earnings preview for the medical devices and diagnostics group.
guidance_changeDexcom lifted its fiscal 2026 revenue outlook to $5.18 billion-$5.25 billion (roughly 11-13% growth) while targeting conversion of nearly 50% of its U.S. user base to the G7 15-Day sensor by year-end.